CAPR Stock Forecast 2025-2026
Distance to CAPR Price Targets
CAPR Price Momentum
10 Quality Stocks Worth Considering Now
Researching Capricor (CAPR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CAPR and similar high-potential opportunities.
Latest CAPR Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, CAPR has a bullish consensus with a median price target of $43.00 (ranging from $25.00 to $77.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $11.82, the median forecast implies a 263.9% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 551.7% upside. Conversely, the most conservative target is provided by Jason McCarthy at Maxim Group, suggesting a 111.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CAPR Analyst Ratings
CAPR Price Target Range
Latest CAPR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CAPR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 20, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $77.00 |
| Mar 20, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $30.00 |
| Mar 17, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $77.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $77.00 |
| Jan 2, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $77.00 |
| Nov 18, 2024 | Jones Trading | Catherine Novack | Buy | Initiates | $40.00 |
| Nov 14, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Maintains | $30.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $77.00 |
| Oct 21, 2024 | Piper Sandler | Edward Tenthoff | Overweight | Initiates | $35.00 |
| Oct 11, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $77.00 |
| Oct 9, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $40.00 |
| Sep 25, 2024 | Maxim Group | Jason McCarthy | Buy | Maintains | $25.00 |
| Sep 25, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $43.00 |
| Sep 24, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $40.00 |
| Sep 23, 2024 | Oppenheimer | Leland Gershell | Outperform | Reiterates | $15.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $8.00 |
| Sep 17, 2024 | Maxim Group | Jason McCarthy | Buy | Reiterates | $12.00 |
| Sep 17, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $15.00 |
| Sep 17, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $40.00 |
| Jul 2, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $40.00 |
Capricor Therapeutics Inc. (CAPR) Competitors
The following stocks are similar to Capricor based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Capricor Therapeutics Inc. (CAPR) Financial Data
Capricor Therapeutics Inc. has a market capitalization of $600.77M with a P/E ratio of -14.2x. The company generates $22.27M in trailing twelve-month revenue with a -181.7% profit margin.
Revenue growth is -7.9% quarter-over-quarter, while maintaining an operating margin of -69.2% and return on equity of -89.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Capricor Therapeutics Inc. (CAPR) Business Model
About Capricor Therapeutics Inc.
Biotechnology company developing cell-based therapeutics.
Capricor Therapeutics generates revenue by developing innovative therapeutics using its proprietary cardiosphere-derived cell technology and engineered exosomes. The company focuses on addressing unmet medical needs in cardiac and skeletal muscle conditions through research and clinical trials, which may lead to collaborations and partnerships in the biopharmaceutical industry.
With a strong emphasis on regenerative and precision medicine, Capricor Therapeutics is positioned as a leader in treating cardiac and muscle diseases. The company's commitment to innovation and collaboration with research institutions enhances its potential for impactful contributions to the healthcare landscape.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
101
CEO
Dr. Linda Marbán Ph.D.
Country
United States
IPO Year
2007
Website
www.capricor.comCapricor Therapeutics Inc. (CAPR) Latest News & Analysis
Capricor Therapeutics will hold its Q4 2024 earnings conference call on March 19, 2025, at 4:30 PM ET, featuring CFO A.J. Bergmann and CEO Linda Marban.
The scheduled earnings call indicates upcoming financial insights and strategic updates from Capricor Therapeutics, which can influence stock performance and investor sentiment.
Capricor Therapeutics (NASDAQ: CAPR) reported its financial results for Q4 and full year 2024, focusing on cell and exosome-based therapeutics for rare diseases.
Capricor Therapeutics' financial results and corporate update could impact stock performance, reflecting its progress in rare disease treatments and investor confidence in its growth potential.
Capricor Therapeutics (CAPR) reported a quarterly loss of $0.16 per share, better than the estimated loss of $0.31, compared to a loss of $0.02 per share a year ago.
Capricor's smaller-than-expected loss signals better financial performance than anticipated, potentially boosting investor confidence and stock value.
Data presented at the 2025 MDA Conference shows a 52% slowing of disease progression and preservation of skeletal muscle function over three years.
The 52% slowing of disease progression in skeletal muscle function could indicate significant advancements in treatment, potentially boosting stock value for related biotech firms.
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
17 days agoNS Pharma, a subsidiary of Nippon Shinyaku Co., Ltd., is based in Paramus, N.J. as of March 10, 2025.
NS Pharma's announcement may indicate strategic developments or product launches, impacting its stock performance and investor sentiment in the pharmaceutical sector.
Capricor Therapeutics (NASDAQ: CAPR) will present at Leerink's Global Healthcare Conference from March 10-12, 2025, and will hold one-on-one investor meetings.
Capricor's participation in a major healthcare conference signals potential for increased visibility and investor interest, which could impact stock performance and investor sentiment.
Frequently Asked Questions About CAPR Stock
What is Capricor Therapeutics Inc.'s (CAPR) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Capricor Therapeutics Inc. (CAPR) has a median price target of $43.00. The highest price target is $77.00 and the lowest is $25.00.
Is CAPR stock a good investment in 2025?
According to current analyst ratings, CAPR has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.82. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CAPR stock?
Wall Street analysts predict CAPR stock could reach $43.00 in the next 12 months. This represents a 263.9% increase from the current price of $11.82. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Capricor Therapeutics Inc.'s business model?
Capricor Therapeutics generates revenue by developing innovative therapeutics using its proprietary cardiosphere-derived cell technology and engineered exosomes. The company focuses on addressing unmet medical needs in cardiac and skeletal muscle conditions through research and clinical trials, which may lead to collaborations and partnerships in the biopharmaceutical industry.
What is the highest forecasted price for CAPR Capricor Therapeutics Inc.?
The highest price target for CAPR is $77.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 551.7% increase from the current price of $11.82.
What is the lowest forecasted price for CAPR Capricor Therapeutics Inc.?
The lowest price target for CAPR is $25.00 from Jason McCarthy at Maxim Group, which represents a 111.6% increase from the current price of $11.82.
What is the overall CAPR consensus from analysts for Capricor Therapeutics Inc.?
The overall analyst consensus for CAPR is bullish. Out of 8 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $43.00.
How accurate are CAPR stock price projections?
Stock price projections, including those for Capricor Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
